Applied Optoelectronics is back in familiar territory this week — the stock dropped 10.8% on Tuesday to close at $170.81, with the same executive team that sold near $190 last month now filing a second round of exits at $166–$173.
The insider story has a new chapter, and it reinforces the prior note rather than contradicting it. On June 12, virtually the entire C-suite sold again simultaneously. The CEO, Thompson Lin, offloaded a combined 145,655 shares across two tranches for roughly $24.8M. The CFO Stefan Murry sold 63,330 shares for around $10.7M. The Chief Legal Officer, two Senior Vice Presidents — all on the same day, all selling. The 90-day net sold value has now crossed $143M. That figure is not a diversification footnote. Two coordinated cluster sales from the same group of insiders, at prices in the $165–$190 range, while the stock trades below those levels, is a signal the market is digesting.
The positioning picture is less charged than the insider activity implies. Short interest has actually eased slightly — it came down roughly 2.7% on the week to 14.8% of the free float, still high in absolute terms but not rising into this selloff. That matters: if professional short sellers were pressing the thesis aggressively, SI would be building, not fading. Borrow remains essentially free at 0.38% cost-to-borrow, and availability is comfortable at 182% of short interest — well above the 52-week trough of 14.8% seen during last year's tightest period. There is no mechanical squeeze pressure here, but there is also no sign that shorts are capitulating. The ORTEX short score has drifted higher this week, closing at 59.9, up from 55 at the start of June — a moderate and rising reading, not an extreme.
Options traders have swung back toward skepticism after the bullish read noted in the prior note. The put/call ratio has eased to 0.83, roughly 1.1 standard deviations below its 20-day average of 1.04. That sounds bullish, but the direction is telling — the PCR ran above 1.1 through most of late May and early June when the stock was sliding from $200, and has only just moved below the mean as the stock dropped another 10.8% Tuesday. The PCR is at its most bullish posture in roughly six weeks, yet the stock keeps falling. Bullish options positioning that doesn't arrest a decline deserves scrutiny.
The Street's read on AAOI is effectively anchored to one firm at this point. Rosenblatt's Mike Genovese raised his target aggressively to $220 on May 8 — the day after Q1 earnings — maintaining a Buy, but that target now sits 29% above the current price. Needham and B. Riley also hold constructive ratings. The bull case rests on Q1's 51% year-on-year revenue growth, the Amazon and Microsoft customer relationships, and expected second-half 2026 acceleration. The bear case is the one the stock keeps illustrating: product mix headwinds, high fixed costs from a vertically integrated model, customer concentration, and a PE ratio still above 64x after the selloff. EPS momentum factor scores remain exceptional — 97th percentile on both 30- and 90-day windows — but the short score rank sits in just the 8th percentile, flagging that the short-interest profile continues to weigh on the overall ORTEX ranking.
Peers sold off sharply Tuesday as well — LITE fell 8.6% and VIAV dropped 7.3% — suggesting a sector-wide bid withdrawal rather than AAOI-specific pressure. Both are up 6–8% on the week despite Tuesday's drop, versus AAOI's 4.9% weekly gain. The optical networking group is moving together, but AAOI's amplified daily swings continue to reflect that elevated short interest and concentrated insider supply overhead.
The next earnings event is scheduled for August 6. With two coordinated insider-selling episodes now on record above current prices, and short interest holding firm at nearly 15% of the float, the question heading into that print is less about whether revenue growth continues and more about whether guidance can justify a valuation that still prices in substantial acceleration.
See the live data behind this article on ORTEX.
Open AAOI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
